JF
IMMX icon

Jump Financial’s Immix Biopharma IMMX Stock Holding History

Jump Financial’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,800
Closed -$177K – 2129
2025
Q4 		$177K Buy
+33,800
New +$139K ﹤0.01% 1771
2024
Q1 		– Sell
-18,500
Closed -$128K – 2068
2023
Q4 		$128K Buy
+18,500
New +$83.8K ﹤0.01% 1639

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Jump Financial's IMMX Position: Q1 2026 in Review

Jump Financial sold out of Immix Biopharma (IMMX) in Q1 2026, closing a stake of 33,800 shares — an estimated $177K sold.

Jump Financial first reported a position in IMMX in Q4 2023 and held it in 2 quarters. The position peaked at $177K in Q4 2025. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Jump Financial reported no remaining Immix Biopharma position as of Q1 2026 after selling out during the quarter.
  • Jump Financial sold 33,800 Immix Biopharma shares in Q1 2026, an estimated $177K.
  • Jump Financial first reported a position in Immix Biopharma in Q4 2023 and held it in 2 quarters.
  • Jump Financial's Immix Biopharma position peaked at $177K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.